![]() ![]() Our commitment to the best science, technology, and practices in the industry is set in motion by our team of deeply committed professionals.įor more information, please visit or follow Acutis Diagnostics on LinkedIn, Facebook, Instagram, and Twitter.Ībout CLX Health / About TrustAssure™ CLX Health, a privately and wholly owned SiriusIQ company, delivers a clinically sound, cloud-based, multi-stakeholder solution which manages a Covid-19 testing ecosystem of physicians, clinics, hospitals, laboratories, and consumers. ![]() We employ and refine state-of-the art tools and procedures to enable practitioners to make better decisions and achieve better outcomes for patients. ![]() ![]() At the leading edge of medical diagnostics, Acutis is dedicated to innovation in the fields of clinical toxicology and molecular detection of infectious diseases. "We are committed to working with our partners to provide customers with easy solutions to meet testing requirements and ensure a safe travel experience."Ībout Acutis Diagnostics Acutis Diagnostics is a specialized clinical laboratory headquartered in Hicksville, New York. We have a directory of more than 15,000 verified COVID-19 testing sites worldwide and are excited to be adding Acutis' key locations serving travelers from New York and New Jersey to help meet demand for testing in this important region as travel increases in the coming months," said Bob Fleury, Global Lab Director for CLX Health. "The TrustAssure platform offers consumers access to the latest testing location data around the world. Acutis is proud to partner with TrustAssure to provide our Acutis Reveal™ SARS-CoV-2 PCR testing available at more than two dozen convenient locations in the New York Metropolitan area." In addition, travelers need to have access to multiple locations so that testing can easily be completed. It is therefore key to have an effective testing program that can provide COVID results in an accurate and expeditious manner. "Even though we are seeing increases in positivity, there has been a demonstrable increase in the volume of air travel. "As we enter this next phase of the COVID pandemic, the need for fast, high quality testing that can detect the presence of variants of concern has never been higher," said Jibreel Sarij, CEO of Acutis Diagnostics, Inc. Several global airlines, including Delta and United, use TrustAssure Global Testing Platform to offer their passengers a seamless option to meet testing requirements for international travel. Simultaneously, with a negative COVID-19 result, their airline will be informed instantly of their passenger's proof of health status and ability to fly through a TrustAssure ReadyToFly message. Once the molecular test is conducted via the Acutis Reveal™ COVID-19 test, the patient will have immediate access to their results in Acutis' secure online portal. From the point of test collection, results are typically returned in about 24 hours, with expedited testing options available that yield results in as few as 16 hours. Once their flight is booked, travelers are able to simply search and secure appointments at convenient testing locations throughout New York and New Jersey. Moreover, we are investing in the machine learning AI tools that will become increasingly important in the interpretation of the complex data sets that our multi-omics analyses will yield."Īcutis Biosciences has developed specialized contract research services to enable biopharmaceutical companies to create value using a holistic approach to "next-generation multi-omics." The company is rolling out the first set of genomic offerings along with immunohistochemistry assays and building out integrated analytics across DNA, RNA, protein, and broader multi-omics.Utilizing TrustAssure's online Global Testing Platform, travelers are able to schedule PCR test appointments instantly and will receive results ahead of their flight. Far too often, we have heard about the industry's dissatisfaction with CROs, whether it be slow turnaround time, incomplete data analytics, or missed opportunities to advance drug discovery with robust biomarker analytics. His extensive experience includes fostering strategic partnerships, implementing customer-focused programs, and growing complex businesses.Īcutis CEO Jibreel Sarij said, "We are reimagining biomarker discovery at the intersection of DNA, RNA, and protein diagnostics and are rewriting the rules to champion our biopharma partners. Tremaine brings over 26 years of experience within the life sciences and CRO industry. In his new role, Tremaine will oversee commercial operations with an emphasis on collaboration and relentless dedication to clients' success. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |